deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT03567577

Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS - a Randomised, Placebo-controlled, Double-blind Trial

Sponsor: Apeptico Forschung und Entwicklung GmbH

Conditions ARDS
Interventions 0.9% Saline Solution Solnatide 25 mg powder for reconstitution for solution for inhalation
Updated 17 times since 2018 Last updated: May 12, 2025 Started: May 23, 2018 Primary completion: Dec 27, 2024 Completion: Dec 27, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on ARDS, this trial is completed. The trial is conducted by Apeptico Forschung und Entwicklung GmbH and has accumulated 17 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jul 2018 – ~Dec 2018 · 5 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Dec 2019 · 4 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Sep 2022 · 11 months · monthly snapshot~Sep 2022 – ~Aug 2023 · 11 months · monthly snapshot~Aug 2023 – ~Mar 2024 · 7 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – present · 14 months · monthly snapshot

Change History

17 versions recorded

  1. Jun 2025 — Present [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  2. Sep 2024 — Jun 2025 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Mar 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  5. Aug 2023 — Mar 2024 [monthly]

    Recruiting PHASE2

▶ Show 12 earlier versions

  1. Sep 2022 — Aug 2023 [monthly]

    Recruiting PHASE2

  2. Oct 2021 — Sep 2022 [monthly]

    Recruiting PHASE2

  3. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  4. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  5. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Feb 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  7. Dec 2019 — Feb 2020 [monthly]

    Recruiting PHASE2

  8. Aug 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  9. May 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  10. Feb 2019 — May 2019 [monthly]

    Recruiting PHASE2

  11. Dec 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  12. Jul 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

    First recorded

May 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Apeptico Forschung und Entwicklung GmbH
Data source: Apeptico Forschung und Entwicklung GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Bonn, Germany , Dresden, Germany , Graz, Austria , Göttingen, Germany , Innsbruck, Austria , Kiel, Germany , Mainz, Germany , Mannheim, Germany , München, Germany and 3 more locations